Log in

NASDAQ:CPAH - CounterPath Stock Price, Forecast & News

$2.11
+0.02 (+0.96 %)
(As of 01/28/2020 03:59 AM ET)
Today's Range
$1.88
Now: $2.11
$2.17
50-Day Range
$0.89
MA: $1.62
$3.92
52-Week Range
$0.83
Now: $2.11
$6.00
Volume438,900 shs
Average Volume4.16 million shs
Market Capitalization$12.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.23
CounterPath Corporation designs, develops, and sells software and services that enable enterprises and telecommunication service providers to deliver unified communications services over Internet protocol based networks in North America and internationally. Its products include Bria softphone suite, which enables consumers and business users to make voice over Internet protocol (VoIP) audio and video calls, send instant messages, manage their presence, share their screen, and collaborate with other users using desktop computers and laptops, smartphones, and tablets; and X-Lite, a standards-based VoIP softphone application that runs on desktop computers. Read More…

Industry, Sector and Symbol

Industry Prepackaged software
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:CPAH
CUSIPN/A
Phone604-320-3344

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.77 million
Book Value$0.54 per share

Profitability

Net Income$-5,010,000.00

Miscellaneous

Employees98
Market Cap$12.58 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive CPAH News and Ratings via Email

Sign-up to receive the latest news and ratings for CPAH and its competitors with MarketBeat's FREE daily newsletter.


CounterPath (NASDAQ:CPAH) Frequently Asked Questions

What is CounterPath's stock symbol?

CounterPath trades on the NASDAQ under the ticker symbol "CPAH."

How were CounterPath's earnings last quarter?

CounterPath, Corp. (NASDAQ:CPAH) announced its quarterly earnings data on Wednesday, December, 11th. The software maker reported ($0.13) earnings per share (EPS) for the quarter. The software maker had revenue of $2.70 million for the quarter. CounterPath had a negative net margin of 34.26% and a negative return on equity of 119.27%. View CounterPath's Earnings History.

When is CounterPath's next earnings date?

CounterPath is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for CounterPath.

Has CounterPath been receiving favorable news coverage?

Media stories about CPAH stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. CounterPath earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the software maker a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for CounterPath.

Are investors shorting CounterPath?

CounterPath saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 61,300 shares, a decrease of 22.1% from the December 31st total of 78,700 shares. Based on an average daily volume of 997,900 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.2% of the shares of the stock are short sold. View CounterPath's Current Options Chain.

Who are some of CounterPath's key competitors?

What other stocks do shareholders of CounterPath own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CounterPath investors own include Inpixon (INPX), Sierra Oncology (SRRA), Biocept (BIOC), Tonix Pharmaceuticals (TNXP), FuelCell Energy (FCEL), Kopin (KOPN), Actinium Pharmaceuticals (ATNM), Pharmacyte Biotech (PMCB), SANUWAVE Health (SNWV) and Athersys (ATHX).

Who are CounterPath's key executives?

CounterPath's management team includes the folowing people:
  • Mr. David L. Karp, Interim CEO, CFO, Treasurer & Corp. Sec. (Age 54)
  • Mr. Todd Carothers, Exec. VP of Sales & Marketing (Age 49)
  • Mr. Michael Doyle Bsc, VP of Technology
  • Steven Hards, VP of Investor Relations
  • Mr. Nemer D. Abourizk, Gen. Counsel

Who are CounterPath's major shareholders?

CounterPath's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.99%). Company insiders that own CounterPath stock include Larry Timlick and Steven Bruk. View Institutional Ownership Trends for CounterPath.

Which major investors are buying CounterPath stock?

CPAH stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for CounterPath.

How do I buy shares of CounterPath?

Shares of CPAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CounterPath's stock price today?

One share of CPAH stock can currently be purchased for approximately $2.11.

How big of a company is CounterPath?

CounterPath has a market capitalization of $12.58 million and generates $10.77 million in revenue each year. CounterPath employs 98 workers across the globe.View Additional Information About CounterPath.

What is CounterPath's official website?

The official website for CounterPath is http://www.counterpath.com/.

How can I contact CounterPath?

CounterPath's mailing address is 300-505 BURRARD STREET, VANCOUVER A1, V7X 1M3. The software maker can be reached via phone at 604-320-3344 or via email at [email protected]


MarketBeat Community Rating for CounterPath (NASDAQ CPAH)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about CounterPath and other stocks. Vote "Outperform" if you believe CPAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPAH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel